Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In Cancer
March 28 2022 - 09:25AM
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage
pharmaceutical company focused on modulating lipid-signaling
pathways to develop treatments for people living with cancer, pain,
and neurological conditions, announced that the Company has entered
into a second collaboration with Richard K. Porter, Ph.D., of the
School of Biochemistry & Immunology at Trinity College Dublin,
Ireland.
Professor Porter’s focus will be on investigating the molecular
basis of fatty acid binding protein (FABP) inhibition in cancer and
the potential of the ART26.12 platform for the treatment of various
tumors. Artelo believes the Trinity College research initiative
will refine and expand the Company’s understanding of the role of
certain FABP inhibitors and could conceivably translate into
multiple compounds tailored to specific cancers from Artelo’s
library of compounds.
“The potential role and implications of FABP inhibition in
different forms of cancer is emerging as a very exciting and
promising advancement in cancer research,” said Professor Porter.
“This collaboration with Artelo will further elucidate the specific
mechanisms by which targeted FABP inhibition may prevent tumor
growth and halt its spreading.”
FABP plays an important role in lipid signaling and is believed
to be an attractive target for cancer drug development. “Large
amounts of human biomarker and animal model data support FABP as an
oncology target. We believe the evidence to date suggests
inhibition of FABP may be relevant in a number of different cancers
with high unmet need. We are pleased to be working on a second
research project with Professor Porter, who has more than 30 years
experience in metabolism and bioenergetics,” said Andrew Yates,
Ph.D., Artelo Biosciences’ Chief Science Officer. “The research is
expected to have multiple data readouts over the next twelve
months.”
About ART26.12ART26.12 is Artelo’s platform of
inhibitors to Fatty Acid Binding Proteins (FABP). FABP is an
intracellular protein that chaperones lipids including
endocannabinoids and fatty acids, and is intended for treatment of
breast cancer, prostate cancer, neuropathic and nociceptive pain,
and anxiety disorders, including post-traumatic stress disorder
(PTSD). Artelo’s near-term goal is to progress its lead compound
into clinical development and assess its activity in models of
cancer and pain. While advancing the lead asset, additional
compound(s) may be identified and selected for advancement in
regulatory-enabling studies.
About Artelo BiosciencesArtelo
Biosciences, Inc. is a clinical-stage pharmaceutical company
focused on modulating lipid-signaling pathways to develop
treatments for people living with cancer, pain, and neurological
conditions. Artelo is advancing a portfolio of broadly applicable
product candidates designed to address significant unmet needs in
multiple diseases and conditions, including anorexia, cancer, PTSD,
pain, and inflammation. Led by proven pharmaceutical executives
collaborating with highly respected researchers and technology
experts, Artelo applies leading edge scientific, regulatory, and
commercial discipline to develop high-impact therapies. More
information is available at www.artelobio.com and
Twitter: @ArteloBio.
Forward Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to Artelo’s product development,
clinical and regulatory timelines, market opportunity, competitive
position, possible or assumed future results of operations,
business strategies, potential growth opportunities and other
statement that are predictive in nature. These forward-looking
statements are based on current expectations, estimates, forecasts
and projections about the industry and markets in which we operate
and management’s current beliefs and assumptions. These statements
may be identified by the use of forward-looking expressions,
including, but not limited to, “expect,” “anticipate,” “intend,”
“plan,” “believe,” “estimate,” “potential,” “predict,” “project,”
“should,” “would” and similar expressions and the negatives of
those terms. These statements relate to future events or our
financial performance and involve known and unknown risks,
uncertainties, and other factors which may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Such factors include those set
forth in Artelo’s filings with the Securities and Exchange
Commission, including our ability to raise additional capital in
the future. Prospective investors are cautioned not to place undue
reliance on such forward-looking statements, which speak only as of
the date of this press release. Artelo undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise, except to the
extent required by applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Mar 2023 to Mar 2024